122 related articles for article (PubMed ID: 28529212)
21. Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade.
Do A; Mittal Y; Liapakis A; Cohen E; Chau H; Bertuccio C; Sapir D; Wright J; Eggers C; Drozd K; Ciarleglio M; Deng Y; Lim JK
PLoS One; 2015; 10(8):e0135645. PubMed ID: 26312999
[TBL] [Abstract][Full Text] [Related]
22. Kidney transplant recipients with hepatitis C virus experienced 100% sustained virologic response at 12 weeks when treated with sofosbuvir-ledipasvir.
Sise ME
Hepatology; 2017 Oct; 66(4):1335-1337. PubMed ID: 28650558
[No Abstract] [Full Text] [Related]
23. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
[TBL] [Abstract][Full Text] [Related]
24. Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C.
Younossi ZM; Park H; Gordon SC; Ferguson JR; Ahmed A; Dieterich D; Saab S
Am J Manag Care; 2016 May; 22(6 Spec No.):SP205-11. PubMed ID: 27266950
[TBL] [Abstract][Full Text] [Related]
25. A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
Med Lett Drugs Ther; 2014 Nov; 56(1455):111-2. PubMed ID: 25372848
[No Abstract] [Full Text] [Related]
26. Successful evolution of morphea after hepatitis C virus eradication with direct-acting antiviral agent treatment.
Guerra Romero AR; Pérez Figueras M; Alonso López S
Rev Esp Enferm Dig; 2019 Dec; 111(12):973. PubMed ID: 31696725
[TBL] [Abstract][Full Text] [Related]
27. The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis.
Tapper EB; Hughes MS; Buti M; Dufour JF; Flamm S; Firdoos S; Curry MP; Afdhal NH
Transplantation; 2017 May; 101(5):987-995. PubMed ID: 27495755
[TBL] [Abstract][Full Text] [Related]
28. Dare to refuse the exorbitant price of Sovaldi!
Prescrire Int; 2014 Nov; 23(154):278. PubMed ID: 25954802
[No Abstract] [Full Text] [Related]
29. Assessing a broader user base for new HCV drug.
Sekkides O
Lancet Infect Dis; 2015 Apr; 15(4):383. PubMed ID: 25809898
[No Abstract] [Full Text] [Related]
30. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MA; Esteban R
J Viral Hepat; 2017 Sep; 24(9):750-758. PubMed ID: 28273410
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.
Gray E; O'Leary A; Bergin C; Cannon M; Courtney G; Crosbie O; De Gascun CF; Fanning LJ; Feeney E; Houlihan DD; Kelleher B; Lambert JS; Lee J; Mallon P; McConkey S; McCormick A; McKiernan S; McNally C; Murray F; Sheehan G; Stewart S; Walsh C; Norris S;
Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):593-601. PubMed ID: 28276815
[TBL] [Abstract][Full Text] [Related]
32. Successful Treatment With Ledipasvir/Sofosbuvir in an Infant With Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency With HCV Allowed Gene Therapy with Strimvelis.
Tucci F; Calbi V; Barzaghi F; Migliavacca M; Ferrua F; Bernardo ME; Canarutto D; Consiglieri G; Recupero S; Calzatini F; Gabaldo M; Lucano C; Casiraghi M; Darin S; Dionisio F; Marktel S; Cestone E; Finazzi R; Mieli-Vergani G; Boeri E; Appleby J; Abd Elaziz D; Ciceri F; Aiuti A; Cicalese MP
Hepatology; 2018 Dec; 68(6):2434-2437. PubMed ID: 30014500
[No Abstract] [Full Text] [Related]
33. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients.
Eckman MH; Woodle ES; Thakar CV; Alloway RR; Sherman KE
Am J Kidney Dis; 2020 Jun; 75(6):857-867. PubMed ID: 32081494
[TBL] [Abstract][Full Text] [Related]
34. China rejects patent on hepatitis C drug sofosbuvir.
Kmietowicz Z
BMJ; 2015 Jun; 350():h3429. PubMed ID: 26105994
[No Abstract] [Full Text] [Related]
35. Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents.
Olafsson S; Tyrfingsson T; Runarsdottir V; Bergmann OM; Hansdottir I; Björnsson ES; Johannsson B; Sigurdardottir B; Fridriksdottir RH; Löve A; Hellard M; Löve TJ; Gudnason T; Heimisdottir M; Gottfredsson M
J Intern Med; 2018 May; 283(5):500-507. PubMed ID: 29512219
[TBL] [Abstract][Full Text] [Related]
36. Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.
Canary LA; Klevens RM; Holmberg SD
Ann Intern Med; 2015 Aug; 163(3):226-8. PubMed ID: 26121095
[No Abstract] [Full Text] [Related]
37. WHO issues guidelines on HCV amid drug cost controversy.
Slomski A
JAMA; 2014 Jun; 311(22):2262-3. PubMed ID: 24915242
[No Abstract] [Full Text] [Related]
38. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
Liu CJ; Chuang WL; Sheen IS; Wang HY; Chen CY; Tseng KC; Chang TT; Massetto B; Yang JC; Yun C; Knox SJ; Osinusi A; Camus G; Jiang D; Brainard DM; McHutchison JG; Hu TH; Hsu YC; Lo GH; Chu CJ; Chen JJ; Peng CY; Chien RN; Chen PJ
Gastroenterology; 2018 Mar; 154(4):989-997. PubMed ID: 29174546
[TBL] [Abstract][Full Text] [Related]
39. US health insurers say Gilead hepatitis C drug too costly.
Clin Infect Dis; 2014 Jul; 59(2):i-ii. PubMed ID: 25105185
[No Abstract] [Full Text] [Related]
40. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.
Fazel Y; Lam B; Golabi P; Younossi Z
Expert Opin Drug Saf; 2015 Aug; 14(8):1317-26. PubMed ID: 26043900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
